NOTTINGHAM, England, January 20, 2016 /PRNewswire/ --
Oncimmune, a leader in early cancer detection, today announced the appointment of Greg Stanley as President of Commercial Operations.
Greg Stanley is a senior executive with a proven track record in launching products and services, developing successful commercial strategies and securing and fostering strategic partnerships across multiple markets, skills that will all be applicable to Oncimmune's next stage of growth.
Greg previously worked for Oncimmune as Chief Commercial Officer from 2007 until 2014 before moving to Opko Health to assume the position of Vice President, Sales & Marketing for the global diagnostics business. Greg has also held various positions at Roche Diagnostics Corporation, World Wide Technology, Radiometer, Chiron Corporation (now Siemens) and Abbott Laboratories.
Previously at Oncimmune, Greg created, implemented and led the commercial strategy and tactical plan for the Company's oncology portfolio including the successful launch of the Company's first commercial product, EarlyCDT®-Lung. In his new role as President of Commercial Operations, Greg will be responsible for consolidating current relationships, appointing new distributors in the US and maximising revenue opportunities for the Company.
Geoffrey Hamilton-Fairley, CEO of Oncimmune commented: "We are very pleased to welcome Greg back to Oncimmune. His prior experience at the Company leaves us in no doubt that he will be able to make an important contribution as we build on our existing market position in the US and look to commercialise EarlyCDT®-Lung in other cancer indications and new markets.
" Commenting on his appointment, Greg Stanley said: "I am very excited to be rejoining Oncimmune and look forward to playing a key role in an ongoing commercial strategy that is already coming to fruition. It is pleasure to return to a team I know well and to be able to focus on bringing EarlyCDT®-Lung to more patients."
EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results were recently presented at the 16th World Conference on Lung Cancer; showing a high cancer detection rate with the majority of these cancers being early stage, resulting in better than expected test performance.
About Oncimmune
Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and can be applied to a very wide range of solid tumour types. The Company's proprietary EarlyCDT® technology platform was launched in 2009 and EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT® tests for liver and ovarian cancer are in final validation.
Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.
For more information: http://www.oncimmune.com
Media Contacts:
UK/Europe:
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
Consilium Strategic Communications
[email protected]
+44(0)20-3709-5813
SOURCE Oncimmune